Global Health Limited
MEDANTA · General/Diversified · NSE
₹1,229
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for MEDANTA yet. Reason: Data Limited.
Updated 3h ago
YieldIQ Score
—
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
46%
ROE
14.0%
Debt/Equity
0.30
WACC
9.5%
Market Cap
₹33,028 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
19.7%
Return on capital employed
EV / EBITDA
34.5×
Enterprise multiple
Debt / EBITDA
1.0×
Leverage vs earnings
Interest Coverage
11.1×
EBIT covers interest
Current Ratio
2.48×
Short-term liquidity
Asset Turnover
0.93×
Revenue per ₹ of assets
Revenue CAGR (3Y)
8.4%
3-year revenue growth
Revenue CAGR (5Y)
13.8%
5-year revenue growth
Ratio Trends
MEDANTA · last 5 annual periods
ROE
14.0%
ROCE
19.7%
Operating Margin
—
Debt / Equity
0.30×
PE
43.4×
EV / EBITDA
21.5×
Historical Financials
MEDANTA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹2167 Cr | ₹2683 Cr | ₹3241 Cr | ₹3692 Cr | ₹4410 Cr | +19.4% |
| EBITDA | ₹490 Cr | ₹677 Cr | ₹872 Cr | ₹906 Cr | ₹1017 Cr | +20.0% |
| EBIT | — | ₹527 Cr | ₹701 Cr | — | — | +7.4% |
| PAT | ₹196 Cr | ₹326 Cr | ₹478 Cr | ₹481 Cr | ₹556 Cr | +29.8% |
| EPS (diluted) | — | ₹12.57 | ₹17.80 | — | — | +9.1% |
| CFO | ₹311 Cr | ₹645 Cr | ₹612 Cr | ₹624 Cr | ₹714 Cr | +23.1% |
| CapEx | ₹-274 Cr | ₹-236 Cr | ₹-279 Cr | ₹-648 Cr | ₹-979 Cr | — |
| FCF | ₹36.8 Cr | ₹409 Cr | ₹333 Cr | ₹-24.2 Cr | ₹-264 Cr | — |
| Total Assets | ₹3146 Cr | ₹4116 Cr | ₹4304 Cr | ₹4766 Cr | ₹5905 Cr | +17.1% |
| Total Debt | ₹1109 Cr | ₹1122 Cr | ₹802 Cr | ₹718 Cr | ₹1190 Cr | +1.8% |
| Shareholders' Equity | ₹1616 Cr | ₹2428 Cr | ₹2906 Cr | ₹3386 Cr | ₹3962 Cr | +25.1% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
MEDANTA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 KIMS Krishna Institute of Medical Sciences Limited | -63.4% | 40 | Data Limited | 10.7% | — |
 ASTERDM ASTERDM | — | — | Pending | 156.9% | — |
 NH Narayana Hrudayalaya Ltd. | -56.4% | 35 | Above Fair Value | 17.8% | — |
 FORTIS Fortis Healthcare Limited | -58.9% | 40 | Above Fair Value | 10.5% | 57.6× |
 MAXHEALTH MAXHEALTH | — | — | Pending | 13.4% | — |
Click a ticker to view its fair-value analysis.
Dividend History
1 ex-dividend event on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹0.50/sh
Last payout
2025-08-22
₹0.50
Peak payout
₹0.50
Trailing yield
0.04%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of MEDANTA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for MEDANTA →
Compare
Head-to-head with peers
Compare MEDANTA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse MEDANTANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.